Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMTNASDAQ:KPTINASDAQ:OGINYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$3.49-3.1%$3.25$2.24▼$28.93$161.67M2.87834,453 shs388,478 shsKPTIKaryopharm Therapeutics$4.59-1.1%$5.19$3.51▼$17.40$39.66M0.3381,958 shs64,571 shsOGIOrganigram$1.37$1.11$0.85▼$2.08$183.36M1.35671,182 shs303,944 shsPRMEPrime Medicine$1.29+4.9%$1.52$1.11▼$8.14$169.37M1.91.33 million shs2.00 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-3.06%+1.45%+2.05%-24.78%-86.65%KPTIKaryopharm Therapeutics-1.08%-13.72%-26.79%-48.86%-72.43%OGIOrganigram0.00%+0.74%+26.85%+4.58%-27.13%PRMEPrime Medicine+4.88%-18.87%-27.53%-56.42%-82.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFDMT4D Molecular Therapeutics2.9145 of 5 stars4.32.00.00.02.71.70.6KPTIKaryopharm Therapeutics3.8322 of 5 stars3.50.00.04.63.12.50.6OGIOrganigram0.4126 of 5 stars0.01.00.00.02.70.01.3PRMEPrime Medicine3.6801 of 5 stars4.40.00.00.02.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56746.86% UpsideKPTIKaryopharm Therapeutics 3.00Buy$43.20841.18% UpsideOGIOrganigram 3.00BuyN/AN/APRMEPrime Medicine 2.86Moderate Buy$11.80814.73% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, FDMT, OGI, and PRME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.005/13/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.005/10/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/9/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $25.005/9/2025FDMT4D Molecular TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.005/9/2025FDMT4D Molecular TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$23K7,029.32N/AN/A$7.20 per share0.48KPTIKaryopharm Therapeutics$142.13M0.28N/AN/A($1.47) per share-3.12OGIOrganigram$194.09M0.94N/AN/A$1.83 per share0.75PRMEPrime Medicine$3.85M44.04N/AN/A$1.37 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$100.84M-$3.18N/AN/AN/AN/A-28.00%-26.16%N/AKPTIKaryopharm Therapeutics-$143.10M-$13.26N/AN/AN/A-52.62%N/A-39.58%8/5/2025 (Estimated)OGIOrganigram-$33.39M$0.10N/AN/AN/A-31.69%-8.59%-6.54%8/12/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ALatest KPTI, FDMT, OGI, and PRME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/A2/28/2025Q4 2024FDMT4D Molecular Therapeutics-$0.80-$0.90-$0.10-$0.90$2.28 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/APRMEPrime Medicine$1.45112.09%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A17.3317.33KPTIKaryopharm TherapeuticsN/A1.702.93OGIOrganigramN/A3.361.85PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%KPTIKaryopharm Therapeutics66.44%OGIOrganigram34.63%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics9.60%KPTIKaryopharm Therapeutics2.98%OGIOrganigram0.09%PRMEPrime Medicine23.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12046.33 million42.85 millionOptionableKPTIKaryopharm Therapeutics3808.64 million122.72 millionOptionableOGIOrganigram860133.84 million126.10 millionOptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableKPTI, FDMT, OGI, and PRME HeadlinesRecent News About These CompaniesHC Wainwright Lowers Earnings Estimates for Prime MedicineMay 24 at 9:03 AM | marketbeat.comPrime Medicine FY2029 EPS Forecast Lowered by HC WainwrightMay 24 at 3:47 AM | americanbankingnews.comWedbush Has Bullish Estimate for Prime Medicine Q3 EarningsMay 23 at 8:07 AM | marketbeat.comWestwood Holdings Group Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)May 23 at 5:58 AM | marketbeat.comWhat is Wedbush's Estimate for Prime Medicine Q3 Earnings?May 23 at 2:43 AM | americanbankingnews.comPrime Medicine (NYSE:PRME) Stock Rating Lowered by HC WainwrightMay 23 at 1:59 AM | americanbankingnews.comPrime Medicine's (PRME) "Neutral" Rating Reiterated at JPMorgan Chase & Co.May 23 at 1:59 AM | americanbankingnews.comPrime Medicine (NYSE:PRME) Downgraded to "Neutral" Rating by HC WainwrightMay 22 at 8:22 AM | marketbeat.comPrime Medicine's (PRME) Neutral Rating Reaffirmed at JPMorgan Chase & Co.May 22 at 8:22 AM | marketbeat.comPrime Medicine (NYSE:PRME) Given New $6.00 Price Target at JMP SecuritiesMay 22 at 3:31 AM | americanbankingnews.com6 Analysts Assess Prime Medicine: What You Need To KnowMay 21 at 7:17 PM | nasdaq.comChardan Capital Issues Pessimistic Forecast for Prime Medicine (NYSE:PRME) Stock PriceMay 21 at 4:15 AM | americanbankingnews.comCEO among 25% of staff out the door at cash-strapped PrimeMay 20, 2025 | thepharmaletter.comPrime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staffMay 20, 2025 | fiercebiotech.comPrime Medicine claims ‘proof of concept,’ but lays off staff in pivotMay 20, 2025 | biopharmadive.comCRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staffMay 20, 2025 | bostonglobe.comPrime Medicine drops after cutting CGD program amid restructuringMay 20, 2025 | msn.comPrime Medicine stock plummets amid restructuring and leadership changesMay 20, 2025 | msn.comPrime Medicine Announces Layoffs, CEO Transition: Retail Gets More BullishMay 20, 2025 | msn.comHead to Head Review: Prime Medicine (NYSE:PRME) and BioCryst Pharmaceuticals (NASDAQ:BCRX)May 20, 2025 | americanbankingnews.comPrime Medicine, Inc.: Strategic Shifts and Leadership Changes Bolster Long-term Buy Rating Amid Near-term VolatilityMay 19, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?3 Tech Leaders Announce Buybacks Totaling $85 BillionBy Leo Miller | May 5, 2025View 3 Tech Leaders Announce Buybacks Totaling $85 BillionThe Top 3 Stock Picks at the World’s Greatest Hedge FundBy Leo Miller | May 2, 2025View The Top 3 Stock Picks at the World’s Greatest Hedge Fund3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketBy Chris Markoch | May 22, 2025View 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketKPTI, FDMT, OGI, and PRME Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$3.49 -0.11 (-3.06%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.58 +0.09 (+2.72%) As of 05/23/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Karyopharm Therapeutics NASDAQ:KPTI$4.59 -0.05 (-1.08%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.59 0.00 (0.00%) As of 05/23/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Organigram NASDAQ:OGI$1.37 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.37 0.00 (0.00%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Prime Medicine NYSE:PRME$1.29 +0.06 (+4.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-1.09%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
